Learn more about the expert speakers participating in the 2018 Highlights of ASH in North America meetings.
Acute Myeloid Leukemia
Alexander E. Perl, MD, University of Pennsylvania
Alexander E. Perl, MD, is an Associate Professor of Medicine in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania. He is an attending physician and a faculty member of the leukemia program at the Abramson Cancer Center of the University of Pennsylvania. His research focuses on molecularly-targeted therapeutics for acute leukemia. His principal expertise is in FLT3 inhibitors for AML and other agents targeting signal transduction, such as tyrosine kinase inhibitors for Ph-like ALL and inhibitors of oncogenic PI3K/AKT/mTOR signaling. Dr. Perl received his medical degree in internal medicine from the Mount Sinai School of Medicine in 1997 and an MS in translational research from the University of Pennsylvania in 2011. He is a board-certified medical oncologist who completed residency training in internal medicine at the University of California – San Francisco and medical oncology fellowship at Johns Hopkins.
Geoffrey L. Uy, MD, Washington University of Medicine
Geoffrey L. Uy, MD, is an Associate Professor of Medicine in the Section of BMT & Leukemia, Division of Oncology at Washington University in St. Louis, and serves as Medical Director for Clinical Research in the Division of Oncology. His research is focused on the development of new agents and treatment approaches for patients with myelodysplastic syndromes and acute leukemias. Specifically, his group is interested in modulating tumor microenvironment interactions as a therapeutic approach for acute leukemias and in the use of next generation sequencing technologies to measure disease response in myelodysplastic syndromes and acute myeloid leukemia.
Alison R. Walker, MD, MPH, The Ohio State University
Alison R. Walker, MD, MPH, is an associate professor in the Division of Hematology in the Department of Internal Medicine at The Ohio State University (OSU). She completed her medical school, internal medicine, and fellowship training in hematology and oncology at the University of Rochester prior to joining the faculty at OSU. Her research focus is in the development of novel therapeutic agents for patients with myeloid malignancies, specifically acute myeloid leukemia and myelodysplastic syndromes. Dr. Walker has led several phase I clinical trials and correlative studies in this regard. Her clinical practice includes predominantly patients with acute leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.back to top
Hematopoietic Stem Cell Transplantation
Michael Bishop, MD, The University of Chicago
Michael R. Bishop, MD, specializes in the diagnosis and treatment of lymphomas and leukemias. In particular, he cares for patients with hematologic malignancies that have not responded to first-line treatments. An expert in hematopoietic stem cell transplantation (bone marrow transplantation), Dr. Bishop and his team are working to address the unique social, economic, physiological, and biological issues that patients face while undergoing this treatment.
Dr. Bishop's research focuses on the prevention and treatment of relapse after stem cell transplantation. Relapse is the primary cause of treatment failure and death after stem cell transplantation. He has served as the primary investigator on studies designed to prevent and treat disease recurrence after transplantation. Specifically, he works on ways to enhance immune effects of the transplanted cells against cancer.
An active contributor to medical literature, Dr. Bishop has authored more than 150 peer-reviewed articles, in addition to more than 30 book chapters and two books on cancer treatment and research. He also serves on the editorial board of numerous scientific journals, including Biology of Blood and Marrow Transplantation.
Dr. Bishop is a dedicated mentor, teaching residents and fellows in classroom, clinical, and research settings. Many of his past trainees hold leadership roles in medical oncology and immunology at academic medical centers and at the National Cancer Institute in Bethesda, Maryland.
Since 2001, Dr. Bishop has consistently been named one of the "Best Doctors in America" by Best Doctors, Inc. He previously served as a senior investigator and as the clinical head of stem cell transplantation for the National Cancer Institute at the National Institutes of Health.
Margaret MacMillan, MD, MSc, University of Minnesota
Margaret MacMillan, MD, MSc, received her master’s degree at the University of Toronto in 1989 and her medical degree at the University of Toronto in 1991. She completed a residency in pediatrics and post-doctoral fellowship in hematology-oncology-BMT at the University of Toronto School of Medicine in 1997. Dr. MacMillan then completed a blood and marrow transplant fellowship at the University of Minnesota in 1999 after which she joined the faculty, where she is currently a Professor of Pediatrics in the Division of Blood and Marrow Transplantation and Clinical Medical Director of the Pediatric BMT Program. She is the principal investigator of 12 phase I/II clinical trials at the University of Minnesota and a key co-investigator on 14 other trials. Dr. MacMillan is also involved in several multi-institutional trials and is a Co-Chair of the BMT CTN Protocol 1501. She has authored more than 120 peer-reviewed publications, reviews, and book chapters.
Dr. MacMillan’s primary research interest is in the development and implementation of novel strategies to prevent and treat acute GVHD. Her other major research focus is in improving the comprehensive care of patients with Fanconi anemia, including reducing early and late effects of hematopoietic cell transplantation and reducing the risk of malignancies.
Dr. MacMillan is a current co-chair of the ASBMT Clinical Research Training Course. She recently completed terms as an ASBMT Director at Large, member of the ASBMT Steering Committee of the Pediatric Tandem meeting, member of the CIBMTR Clinical Trials Advisory Committee, and member of the ASH Scientific Subcommittee on Bone Marrow Failure. She is a past chair and current member of the DOD Bone Marrow Failure Research Program Integration Panel.back to top
Donald Arnold, MD, MSc, McMaster University
Donald Arnold, MD, MSc, obtained his medical degree from McGill University in 1997 and his Master’s in Clinical Epidemiology from McMaster University in 2006. He completed his residency training in internal medicine at the Sir Mortimer B. Davis Jewish General Hospital in Montreal in 2001, hematology at McMaster University in 2003, and transfusion medicine with the Canadian Blood Services (CBS) in 2005. Dr. Arnold also completed a fellowship in transfusion science funded jointly by the Canadian Institutes for Health Research and CBS. He is an assistant professor in the department of Medicine at McMaster University as of July 2007.
Rachel Grace, MD, MMSc, Boston Children’s Hospital
Rachael Grace MD, MMSc, is an Assistant Professor at Harvard Medical School and is the director of the Boston Children’s Hospital Hematology Clinic and the Hematology Clinical Research program. Her research is focused on immune cytopenias and congenital hemolytic anemias. Dr. Grace is the director of the ITP Consortium of North America, a research consortium of physician investigators focused on improving care in pediatric ITP.
Lawrence Rice, MD, Weill Cornell Medical College
Lawrence Rice, MD, graduated from Emory School of Medicine in 1974. He completed an internal medicine residency and hematology fellowship, and then joined the full-time faculty at Baylor College of Medicine in Houston, rising to Professor of Medicine and Professor of Thrombosis Research. For more than 20 years, he was Hematology Program Director and director of the required medical student hematology/oncology course. Dr. Rice’s primary affiliation changed in 2007 to Chief of Hematology at Houston Methodist Hospital and Professor of Medicine at Weill Cornell Medical College, Houston campus.
Dr. Rice’s active consultative hematology practice routinely manages such disorders as congenital TTP, paroxysmal nocturnal hemoglobinuria, and Evans syndrome. He has received numerous awards for his teaching of subspecialty fellows, medical residents, and students. In 2003, he was inducted in the inaugural class of the Baylor Medicine Educator Hall of Fame. In 2010, he received the Edward C. Lynch Outstanding Teacher Award from Houston Methodist Internal Medicine residents, the Houston Methodist GME Teacher of the Year Award, the Hematology Honorary Fellow (Outstanding Teacher) Award from MD Anderson Hematology/Oncology fellows, and the Hematology Educator of the Year from Baylor Hematology/Oncology fellows. In 2017, Dr. Rice was named Hematology Faculty Educator of the Year by the first Houston Methodist hematology/oncology fellow graduating class. He has published more than 100 peer-reviewed manuscripts and dozens of book chapters and monographs. Dr. Rice’s research interests include thrombocytopenias (HIT, ITP, TTP) and anemias (iron metabolism, erythropoietin, hemolysis).back to top
Disorders of Hemostasis
Alfonso Iorio, MD, PhD, McMaster University
Alfonso Iorio, MD, PhD, is Associate Professor of Clinical Epidemiology & Biostatistics and Medicine at McMaster University. He is chief of the Health Information Research Unit (HiRU) and of the Hamilton-Niagara Hemophilia Program. Dr. Iorio is the principal investigator of the Canadian Hemophilia Surveillance Study (CHESS), the Canadian “branch” of the EUHASS surveillance scheme, and of the Web Application for Population Pharmacokinetic in Hemophilia (WAPPS) project.
Dr. Iorio is Associate Editor for Congenital Blood Coagulation Disorders of the Cystic Fibrosis and Genetic Disorders Review Group of the Cochrane Collaboration, a member of the Data and Demographics Committee of the World Federation of Hemophilia, and a member of the Association of Hemophilia Center Directors of Canada. He is a medical advisor to the Canadian Hemophilia Society and a member of the Research Advisory Committee of the Canadian Hemophilia Society. Dr. Iorio is co-principal investigator of the McMaster GRADE working group supporting the National Hemophilia Foundation Guideline Program. He serves on the editorial boards of the American College of Physicians Journal Club, Journal of Thrombosis and Haemostasis, Haemophilia, and the Rare Diseases BEST Practice Journal.
Dr. Iorio's current research interests include knowledge translation research and medical informatics, focusing on the assessment of the impact of knowledge dissemination through information technology and web-based systems, and systematic review methodology, particularly applied to individual patient databases and prognostic questions. His research interests also lie in risk prediction and stratification, with a focus on inhibitor development and in meta-analysis application to observational trials and individual patient data. Dr. Iorio’s clinical interests are in thrombosis and haemostasis, particularly recurrent VTE and epidemiology of hemophilias.
Sarah O'Brien, MD, Nationwide Children’s Hospital
Sarah O’Brien, MD, MSc, is a pediatric hematologist at Nationwide Children’s Hospital and an Associate Professor of Pediatrics at The Ohio State University College of Medicine. She serves as the Director of Experimental Therapeutics for the Division of Pediatric Hematology/Oncology/BMT and leads a multi-disciplinary young women's hematology clinic. Dr. O’Brien’s clinical and research interests include the evaluation and diagnosis of mild bleeding disorders, pediatric thrombosis and thromboprophylaxis, and the intersections between hematology and women’s health.
Anita Rajasekhar, MD, MS, University of Florida
Anita Rajasekhar, MD, MS, is an Associate Professor at the University of Florida in Gainesville, Florida. She is board certified in internal medicine, medical oncology, and hematology. Her primary clinical and research specialization is in non-malignant hematology, specifically thrombosis and hemostasis. Dr. Rajasekhar is the adult medical director of the University of Florida Hemophilia Treatment Center. She is actively involved in the American Society of Hematology (ASH) and has participated as a fellow and faculty mentor in the ASH Clinical Research Training Institute. She also serves on the ASH Committee on Quality and has a leading role in venous thromboembolism guideline development both as a guideline panel member and as the conflict-of interest officer. Dr. Rajasekhar is an active member of the ASH Choosing Wisely Task Force, which promotes cost-conscious and evidence-based care. Her research has focused on prevention and treatment of venous thromboembolism in special populations. Dr. Rajasekhar was awarded an ASH Scholar Award to evaluate barriers to inferior vena cava filter removal.
Char M. Witmer, MD, MSCE, The Children’s Hospital of Philadelphia
Char M. Witmer, MD, MSCE is a pediatric hematologist at The Children’s Hospital of Philadelphia (CHOP) in Philadelphia, Pennsylvania. She is board certified in Pediatric Hematology Oncology and is currently the assistant director of the CHOP Hemostasis and Thrombosis Center. Dr. Witmer is a clinical researcher with a master’s degree in epidemiology and has a research focus that mirrors her clinical expertise in pediatric hemostatic and thrombotic disorders. She also has an interest in preventing hospital acquired conditions and has received formal training in quality improvement methodology. She currently is the CHOP physician lead for the prevention of hospital-acquired venous thromboembolism. In addition, she serves as a co-leader for the Solutions for Patient Safety National Children’s Network of over 100 US pediatric hospitals to prevent pediatric venous thromboembolism.back to top
Myeloproliferative Neoplasms, Including Chronic Myeloid Leukemia
Michael Mauro, MD, Memorial Sloan Kettering Cancer Center
Michael Mauro, MD, is a hematologist in New York, New York, and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Geisel School of Medicine at Dartmouth and has been in practice for more than 20 years.
Laura Michaelis, MD, Medical College of Wisconsin
Laura Michaelis, MD, is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, bone marrow failure syndromes, and myeloid disorders. She graduated from Harvard Medical School in 2000, then completed her internal medicine residency at Brigham and Women’s Hospital in Boston, Massachusetts. Dr. Michaelis received the Arnold Dunne Award for compassionate care in the practice of medicine during her residency. In 2003, she relocated to Chicago, Illinois, where she completed a hematology-oncology fellowship at The University of Chicago. Dr. Michaelis served as an assistant professor of medicine and program director of the hematology and oncology fellowship program at Loyola University Medical Center before joining the Medical College of Wisconsin.
Her clinical research focuses on leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. She serves as director of inpatient services for the division of hematology/oncology and was appointed to be one of the associate vice chairs of the department of medicine. Dr. Michaelis is board-certified in hematology and medical oncology.
Raajit K. Rampal MD, PhD, Memorial Sloan Kettering Cancer Center
Raajit K. Rampal, MD, PhD, is an assistant member at Memorial Sloan Kettering Cancer Center and clinical director of the leukemia service. He received his undergraduate degree in biochemistry from the University of Rochester. Dr. Rampal subsequently went on to train in the Medical Scientist Training Program (MSTP) at Stony Brook University. His PhD work focused on the regulation of the Notch signaling pathway by glycosyltransferases. This was followed by internship and residency at The University of Chicago, as part of the Physician-Scientist Development Program. Dr. Rampal went on to do a fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center. During fellowship, he joined the laboratory of Dr. Ross Levine. The focus of his research has been to utilize genetic insights from primary patient samples to elucidate mechanism of pathogenesis in acute myeloid leukemia (AML) and the Philadelphia-chromosome negative myeloproliferative neoplasms (MPN). These genetic insights are being used to develop novel models of AML and MPN, and to develop mechanism-based clinical trials.back to top
Olatoyosi Odenike, MD, The University of Chicago
Olatoyosi Odenike, MD, is an Associate Professor of Medicine at The University of Chicago. Her clinical research and medical practice is focused on myeloid malignancies, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and acute myeloid leukemia. Dr. Odenike has a particular interest in new drug development in these diseases and has authored and co-authored several early phase trials and manuscripts focused on this patient population. She currently serves as Co-Director of The University of Chicago Phase II Personalized Care Consortium and is a member of the Alliance Leukemia Core Committee. Dr. Odenike has served on various professional committees, including as Chair of Educational Programs focused on MPNs for the American Society of Hematology (ASH). She is also a member of the ASH Consult a Colleague Program. Dr. Odenike currently serves as a member of the Aplastic Anemia/MDS International Foundation Medical Advisory Board. In addition, she is a standing member of the Molecular and Cellular Hematology NIH Study Section and serves on the Medical Oncology Board Examination Committee of the American Board of Internal Medicine.
Dr. Odenike received her pre-medical training at the University of Ife, Nigeria, and her medical degree from the University of Ibadan, Nigeria. She completed her residency training in internal medicine and pediatrics at the University of Illinois and her hematology/oncology fellowship training at The University of Chicago.
Mikkael Sekeres, MD, MS, Cleveland Clinic
Mikkael Sekeres, MD, MS, is Professor of Medicine, Director of the Leukemia Program, and Vice Chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute. He is also Deputy Associate Director for Clinical Research of the Case Comprehensive Cancer Center in Ohio. Dr. Sekeres earned a medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. He completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital and a fellowship in hematology-oncology at the Dana-Farber Cancer Institute in Boston.
Dr. Sekeres chaired the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration and is co-chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndrome (MDS) International Foundation and of the MDS Research Fund of the Dresner Foundation. An invited speaker at numerous meetings, grand rounds, and conferences, Dr. Sekeres is a member of the American Society of Hematology, where he is also on the Executive Committee, the American Society of Clinical Oncology, and the Southwest Oncology Group—Leukemia Committee. His research focuses on patients with MDS and older adults with acute myeloid leukemia. Dr. Sekeres has been the national and international primary study investigator on several phase I/II/III trials.
Dr. Sekeres is the author or co-author of 300 articles and 400 abstracts published in leading journals, including Blood. He is the co-author of six books and the editor-in-chief of ASH Clinical News. Dr. Sekeres is also on the editorial board of several journals and is a frequent essayist for The New York Times.
Amer Zeidan, MBBS, Yale University
Amer Zeidan, MBBS, MHS, is an Assistant Professor of Medicine (Hematology) at Yale University. He completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan received his MBBS degree from the Faculty of Medicine, University of Jordan in Amman, Jordan before completing his internal medicine residency at Rochester General Hospital in Rochester, New York.
Dr. Zeidan specializes in the management of MDS and acute myeloid leukemia (AML). He is a nationally recognized expert in the clinical management of these diseases and is a member of the National Comprehensive Cancer Network (NCCN) clinical guideline panel for MDS. The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for MDS, AML, and other hematologic malignancies. He is the principal investigator on several clinical trials in MDS, AML, and other hematologic malignancies. Dr. Zeidan especially focuses on the use of immunotherapies including immune checkpoint inhibitors for myeloid malignancies.
The second area of research interest for Dr. Zeidan is effectiveness and outcomes research in hematologic malignancies, a type of research that evaluates how much benefit patients achieve from existing treatments at the real-world community level in comparison to what is seen in the controlled clinical trials setting. Dr. Zeidan conducts this research within the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale University.
He has been awarded the American Society of Clinical Oncology Young Investigator Award, the Aplastic Anemia and MDS International Foundation (AAMDSIF)/Ed Evan’s Foundation-MDS Clinical Research Consortium Fellowship award, The Tito Bastianello Young Investigator Award, and multiple abstract achievement and travel awards. Dr. Zeidan has presented his research at multiple national and international meetings and is an author on more than 110 peer-reviewed publications and book chapters.back to top
Robert Chen, MD, City of Hope Medical Center
Robert Chen, MD, is an associate professor in the Department of Hematology/HCT at City of Hope Medical Center. He is also an associate director of the Toni Stephenson Lymphoma Center. Dr. Chen’s research focuses on developing novel therapeutics in lymphomas and also stem cell transplantation. He has authored more than 70 peer reviewed papers and given national and international lectures on the treatment of lymphomas. Dr. Chen has also received the NCI Cancer Clinical Investigator Team Leadership Award.
Michelle Fanale, MD, The University of Texas MD Anderson Cancer Center
Michelle Fanale, MD, received her medical degree through the New Jersey Medical School-University of Medicine and Dentistry of New Jersey (NJMS-UMDNJ). She completed her internal medicine residency at the Mayo Clinic Rochester and her hematology/oncology fellowship at The University of Texas MD Anderson Cancer Center. She has been a faculty member in the department of lymphoma/myeloma at UT MD Anderson Cancer Center since 2005 and is currently an associate professor.
Dr. Fanale’s clinical and research interests are in Hodgkin, T-cell, Burkitt, and other c-MYC positive lymphomas as well as HIV-associated lymphomas. She is well published in her areas of interest and is an invited speaker both nationally and internationally. Dr. Fanale is focused on developing new therapies which can first be evaluated in relapsed/refractory disease and then integrated into earlier lines of therapy both in combination with each other and with chemotherapy. She leads a multitude of clinical trials ranging from phase I to phase III and was a key principal investigator for the FDA approvals of brentuximab vedotin, nivolumab, and pembrolizumab. Outside of MD Anderson, Dr. Fanale is the co-founder of the North American Hodgkin Lymphoma Consortium (NAHLC) and is the co-chair of the Mayo Clinic’s Academic and Community Cancer Research United (ACCRU) Lymphoma Committee. Dr. Fanale is proud to mentor multiple junior faculty and fellows through their career development and is appreciative for the outstanding research and clinic team members that support her care of patients and clinical trial work.
Anas Younes, MD, Memorial Sloan Kettering Cancer Center
Anas Younes, MD, is a medical oncologist and chief of the lymphoma service at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Younes works with 16 world-class lymphoma experts who are devoted to caring for people with all types of Hodgkin lymphoma and non-Hodgkin lymphoma. They collaborate closely with colleagues across MSKCC to provide personalized, comprehensive care for each patient. The MSKCC clinical trials research program is leading the way in discovering new treatment options that are improving outcomes and quality of life for people with lymphoma. These include immunotherapies, targeted therapies, and combination therapies.
Dr. Younes joined MSKCC in 2013 with two decades of experience in treating and managing people with lymphoma at The University of Texas MD Anderson Cancer Center in Houston. He has an extensive background in translational scientific research, which means that he uses findings in his lab to fuel the discovery of new therapies and treatment strategies. Dr. Younes is particularly interested in developing novel targeted therapies and linking them to biomarkers that can help match people with the most effective and least toxic medicines.
Dr. Younes is leading a Specialized Center of Research collaborative grant funded by the Leukemia & Lymphoma Society and focused on the development of immune therapy for lymphoma. He serves on the Scientific Advisory Board of the Lymphoma Research Foundation and is a past member of the National Cancer Institute Lymphoma Steering Committee.back to top
Paul M. Barr, MD, University of Rochester
Paul M. Barr, MD is an Associate Professor of Medicine and Oncology at the University of Rochester Medical Center in Rochester, New York. He received his medical degree from Northeastern Ohio Medical University. His internal medicine and hematology/oncology training was completed at Case Western Reserve University where he also served as Chief Medical Resident. Joining the University of Rochester lymphoma program in 2010, his primary research focus is on novel drug development for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Dr. Barr’s current efforts revolve around the development of novel combinations incorporating inhibitors targeting the B cell receptor signaling pathway and are supported by a career development grant awarded by the Lymphoma Research Foundation.
As an investigator, Dr. Barr remains dedicated to clinical and translational research initiatives. He has led several single institution, multi-center and cooperative group studies evaluating novel agents in lymphoma and CLL. Dr. Barr is a member of the SWOG lymphoma committee, leading SWOG 1608, the ongoing follicular lymphoma National Clinical Trial Network study. He was also the principal investigator for SWOG 1108, the first clinical trial in peripheral T-cell lymphoma completed within the U.S. intergroup. Beyond his individual research interests, Dr. Barr is a strong advocate for oncology clinical research. He serves as the Medical Director of the Clinical Trials Office for the Wilmot Cancer Center overseeing all industry sponsored, cooperative group, and investigator initiated studies.
Grzegorz Nowakowski, MD, Mayo Clinic
Grzegorz Nowakowski, MD, has a clinical focus on hematology and hematologic cancers. Specifically, he is focused on the identification of novel prognostic markers in chronic lymphocytic leukemia using phage display peptide libraries. Dr. Nowakowski contributes to research in Mayo Clinic's Center for Individualized Medicine. He is also active in education and has been recognized for his leadership in Mayo's hematology/oncology fellowship.
Laurie Sehn, MD, MPH, British Columbia Cancer Agency
Laurie Sehn, MD, MPH, has been a Clinical Assistant Professor with the British Columbia Cancer Agency and University of British Columbia, where she is a medical oncologist and clinical investigator with the lymphoma tumor group, since 1998. Dr. Sehn graduated from McGill Medical School in Montreal, Canada, in 1991 and received her training in internal medicine at Columbia Presbyterian Medical Center in New York. She was trained in haematology-oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital and received a Masters of Public Health degree from Harvard School of Public Health in 1997. Prior to returning to Canada, she spent a year at the Dana-Farber Cancer Institute as a bone marrow transplant specialist. Dr. Sehn has served on the Board of Directors of the Lymphoma Foundation Canada (LFC) since 2002 and is currently the Director of Research Fellowships for the LFC. Hers research interests include all of the lymphoid cancers, with particular interest in the biology and treatment of large cell lymphoma, the application of new imaging techniques such as PET scanning to lymphoma management, and innovative new approaches to treatment. Dr. Sehn is the lead investigator of a major new clinical trial focusing on the use of PET scanning in the therapy of large cell lymphoma.
Andrei Shustov, MD, University of Washington
Andrei Shustov, MD, specializes in treating T-cell non-Hodgkin lymphoma, cutaneous T-cell lymphoma, Hodgkin lymphoma, and acute lymphocytic leukemia.back to top
Marc Carrier, MD, MSc, University of Ottawa
Marc Carrier, MD, MSc, is an associate professor in the faculty of Medicine, Department of Medicine, and a scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. He holds a Tier 2 Research Chair in Venous Thromboembolism and Cancer from the University of Ottawa and received a New Investigator Award from the Heart and Stroke Foundation of Canada.
Dr. Carrier’s clinical research is focused in venous thromboembolic disease and cancer, including cancer screening, prevention, and management. He is currently the principal investigator on four peer-reviewed clinical trials – two with the Heart and Stroke Foundation and two with the Canadian Institute of Health Research – as well as numerous industry-sponsored trials. Dr. Carrier has published important systematic reviews and has had multiple international speaking invitations to speak on the topics of cancer and thrombosis.
Agnes Y.Y. Lee, MD, University of British Columbia
Agnes Y.Y. Lee, MD, is the Medical Director of the Thrombosis Program for Vancouver Coastal Health and a Professor of Medicine at the University of British Columbia, Vancouver, Canada. Her primary clinical research interest is in cancer-associated thrombosis.
Dr. Lee earned her Doctorate of Medicine and completed her residency in internal medicine at the University of British Columbia. She obtained her training in Hematology and Thrombosis and earned her Masters of Science in Health Research Methodology at McMaster University, Hamilton, Canada.
Dr. Lee was Principal Investigator of the CLOT and CATCH trials, evaluating the use of low molecular weight heparin for the long-term treatment of cancer-associated thrombosis. She is a member of clinical practice guideline committees with the American Society of Clinical Oncology and the American Society of Hematology, and served as Chair of the Subcommittee on Hemostasis & Malignancy with the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. She participates in Data and Safety Monitoring Boards and Expert Scientific Panel at the National Institute of Health. She is a member of the Guidelines and Protocols Advisory Committee to the Medical Services Commission of British Columbia.back to top
Sickle Cell Disease
Amanda Brandow, DO, MS, Medical College of Wisconsin
Amanda Brandow, DO, MS, is an Associate Professor of Pediatrics at the Medical College of Wisconsin/The Children’s Hospital of Wisconsin in the section of hematology/oncology/bone marrow transplantation. Dr. Brandow provides clinical care for patients with sickle cell disease and other benign hematologic disorders at Children’s Hospital of Wisconsin. Dr. Brandow’s research is focused on understanding the biology of pain in patients with sickle cell disease with the goal of developing novel drugs to treat sickle cell disease pain that are opioid-sparing. Her research is funded by the National Heart Lung and Blood Institute at the National Institutes of Health, the American Society of Hematology, and other local and regional research foundations. Dr. Brandow is the current chair of the evidence-based guideline panel for sickle cell disease acute and chronic pain through the American Society of Hematology. Dr. Brandow also serves as an Associate Editor of the Journal of Pediatric Hematology/Oncology.
Robert Liem, MD, Ann & Robert H. Lurie Children's Hospital of Chicago
Robert Liem, MD, is Director of the Comprehensive Sickle Cell Program at Ann & Robert H. Lurie Children's Hospital of Chicago. His clinical interests center on hemoglobin disorders, including pediatric and adult sickle cell disease and thalassemia. Dr. Liem is also a clinical investigator with active research programs in these areas. His major research interests focus on exercise responses, inflammation and vascular function as well as their impact on cardiopulmonary fitness, clinical outcomes, and physical functioning in children and young adults with sickle cell anemia. Dr. Liem is the principal investigator of several other protocols at Lurie Children's Hospital that are aligned with his interests in exercise physiology, free-living physical activity, habitual exercise patterns, and aerobic training in this population. Other areas of clinical and research focus include patient-reported outcomes, quality of life, transition to adult care, patient-centered medical homes, health disparities, and parental decision making regarding research participation in sickle cell disease and thalassemia.
Angela Rivers, MD, PhD, University of Illinois Hospital
Angela Rivers, MD, PhD, has a clinical interest in the transition of sickle cell disease patients. She sees patients in the Sickle Cell Transition Adolescent-Adult Readiness Clinic (STAR) and the general pediatric hematology oncology clinic. Her research interest focuses on the adeno-associated virus as a vector for gene therapy in sickle cell disease.back to top
Chronic Lymphocytic Leukemia
Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute
Jennifer R. Brown, MD, PhD, is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts. Dr. Brown completed her bachelor’s and master’s degrees in molecular biophysics and biochemistry at Yale. She completed her MD and PhD in molecular genetics at Harvard Medical School in 1998. Dr. Brown served as an intern and resident in internal medicine at Massachusetts General Hospital and then completed her fellowship in hematology and medical oncology at the Dana-Farber Harvard Cancer Center. She joined the faculty of Dana-Farber Cancer Institute and Harvard Medical School in 2004. Dr. Brown has an active clinical-translational research program in CLL, with particular focus on novel therapeutics and genomics of CLL, including in particular the inherited predisposition to CLL and the implementation of genomic technology in the clinic. She is an active member of the CLL Research Consortium and serves on the Alliance Leukemia and Leukemia Correlative Science Committees. To date, Dr. Brown has published more than 170 papers in the scientific literature, predominantly in CLL.
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute
Matthew S. Davids, MD, MMSc, is Associate Director of the CLL Center and Director of the Lymphoma BioBank at Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. He has an active translational research program in CLL, studying Bcl-2 biology in his laboratory and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of Dr. Davids’ work has focused on the clinical development of the Bcl-2 inhibitor venetoclax and utilizing checkpoint blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation.
Richard Furman, MD, Weill Cornell Medical College
Richard Furman, MD, is Director of the CLL Research Center at Weill Cornell Medicine and a member of the lymphoma and myeloma service in the division of hematology/oncology. His area of focus is on the development of non-chemotherapeutic approaches to treating chronic lymphocytic leukemia. Dr. Furman has played an integral part in the development of ibrutinib and idelalisib.back to top
Plasma Cell Disorders (Myeloma)
Faith Davies, MD, University of Arkansas
Faith Davies, MD, is a professor of medicine and the director of the phase I clinical trials program for both the Myeloma Institute and the Winthrop P. Rockefeller Cancer Institute at UAMS. She earned her medical degree from the University of Wales College of Medicine and completed her general medical training in Cardiff and Birmingham. Dr. Davies completed her hematology specialist training in Leeds and London. During this time, she also undertook research at the University of Leeds and the Dana-Farber Cancer Institute in Boston into the biology and treatment of multiple myeloma, concentrating on a number of potential new drugs and genetic technologies and their applications to myeloma.
Dr. Davies is recognized internationally for her focus on innovative targeted molecular therapies as well as her expertise in the treatment of relapsed refractory disease. Her focus has been on combining laboratory-based research on targeted approaches to myeloma therapy with clinical work involving the introduction of new drugs in the clinical setting, with an emphasis on phase I, II and II clinical trials. Dr. Davies is a member of the scientific advisory boards of both Myeloma UK and the International Myeloma Foundation.
She has received funding for her research from the Cancer Research UK, Kay Kendall Leukaemia Fund, Department of Health, Laeukemia Research Fund, and British Society of Haematology. Dr. Davies has published more than 100 papers in peer-reviewed journals and has contributed to a number of book chapters and reviews on myeloma biology and treatment. She is also a reviewer for a number of international journals and grants.
Shaji Kumar, MD, Mayo Clinic
Shaji K. Kumar, MD, is a consultant in the Division of Hematology and Professor of Medicine at Mayo Clinic Cancer Center in Rochester, Minnesota. He is the Chair of the Myeloma, Amyloidosis, Dysproteinemia group at Mayo Clinic. Dr. Kumar also serves as Medical Director for the Cancer Center Clinical Research Office which oversees the development, activation, conduct, and monitoring of interventional trials across the three locations of Mayo Clinic Cancer Center. He is Chair and Value Pathways Task Force Member of the NCCN Multiple Myeloma/Systemic Light Chain Amyloidosis/ Waldenström's Macroglobulinemia Panel. He also serves as the co-chair for the NCI Myeloma Steering Committee.
Nina Shah, MD, University of California – San Francisco
Nina Shah, MD, is a hematologist who specializes in the treatment of multiple myeloma, a type of cancer affecting the blood marrow. Dr. Shah treats patients at the Hematology and Blood Marrow and Transplant Clinic. Her areas of professional interest include the intersection of immunology and oncology and helping patients fight multiple myeloma by boosting their immune systems. An associate professor at the University of California – San Francisco, Dr. Shah belongs to the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Blood and Marrow Transplantation. She speaks Bengali and Spanish.
Keith Stewart, MBChB, Mayo Clinic
Keith Stewart, MBChB, is a consultant in the Division of Hematology and Oncology, Department of Internal Medicine at Mayo Clinic in Arizona. He currently serves as the Carlson and Nelson Endowed Director of the Center for Individualized Medicine and is recognized as the Vasek and Anna Maria Polak Professor of Cancer Research. Dr. Stewart holds the academic rank of professor of medicine, Mayo Clinic College of Medicine. He joined the staff of Mayo Clinic in 2005.
back to top